IPHARMA MASTERON 200 (200MG/ML DROSTANOLONE ENANTHATE=10ML)
- Androgenic: 25-40 (High)
- Anabolic: 62-130 (Moderate)
- Standard: Testosterone
- Drug Class: Androgenic/Anabolic steroid (For injection)
- Average Reported Dosage: Men 300-500-mg weekly / Women 100-350mg weekly
- Active-Life: 2-3 days for Propionate / 10-14 days for Enanthate
- Water Retention: No
- Acne: Yes
- Liver Toxic: No
- High Blood Pressure: Rare
- DHT Conversion: None, DHT derivative
- Aromatization: No
- Decreases HPTA function: Low suppression in most cases
- Moderate anti-estrogenic
Masteron is a highly androgenic injectable steroid that is a synthetic derivative of DHT (dihydrotestosterone). Since DHT does not aromatize to estrogens, there was no noted water retention during administration. If a bodybuilder had achieved a low body fat level, this drug was reported to dramatically improved shape and hardness in muscle tissue while augmenting the vascular appearance of a contest-ready athlete. Normally, Masteron was used only during the last 3-5 weeks before a show as part of a pre-contest stack. In this case, 100-mg was commonly injected every second or third day (2-3 times weekly) by males and at a dosage of 50mg every other day by most women who reported use. Additionally, according to available literature, Masteron is quite anti-catabolic and anti-estrogenic in nature due to receptor inhibition. So the reported characteristics of this drug do have supportive clinical validation to consider.
Combined with so-called mass steroids, Masteron did aid in a rapid build-up of strength and mass even with its relatively moderate anabolic qualities. However, Masteron was not reported to be the best choice for this purpose by those polled. DHT can promote hair loss and prostate disorders in prone individuals though it is not well documented as to whether or not deviants of the DHT structure can in all cases do the same.
Masteron has a receptor binding ability 3-5 times greater than of testosterone. This means that the drug can hang out longer in androgen receptor sites and is not easily displaced. The result should be increased AAS activity.
An interesting facet of Masteron is the way it acts as an anti-estrogen. This is due to its ability to compete for the aromatase receptor. As the reader is aware of by now, many AAS is capable of conversion to estrogens. The process is caused by an enzyme called aromatase. (Of course, the process of AAS conversion to estrogen is referred to as aromatization) If a drug has the ability to inhibit the enzyme at its own receptor and still act as a powerful non-aromatizing AAS, it’s interesting and unusual to me.
My personal experiences with this drug have always been favorable with no negative side effects. Additionally, I feel that the drug has had value as a sort of AAS moderator. Let me explain this. Masteron has a high SHBG and albumin binding rate. Since these two hormone-binding proteins prevent AAS from merging with their receptors, some would assume this is a bad thing. Masteron is 3-5 times more active than testosterone, so the unbound portion circulating in the bloodstream goes a long way. Since the drug binds a higher percentage of SHBG and albumin, any other AAS co-administered with it remains in an unbound/active/free state to a greater extent and is able to induce a greater response. This is an example of noted drug synergy common to protocols reported as most effective yet requiring lower dosages to accomplish a specific result. The implication is that lower dosages of co-administered drugs allowed a decrease in negative side effects.
A point of interest is that two OTC prohormones in the United States have similar effects to Masteron (through oral administration is not the most effective delivery method and injection type administration would be illegal in most countries) (1) 5a-androst-1-en-3b,17b- dione (2) 5a-androst-en-3b,17b-diol. My personal research has shown that there is a realistic approach to an orally administered version of the latter of the two drugs that have shown great promise. We will complete the final testing soon before turning the project over to the crazies at Hazardous Materials Supplements. Personally, I am totally stoked about the project due to its vast application potential in the world OTC supplemental industry. The key is a compound from Eastman that allows lipophilic substances to become hydrophilic (Oil soluble to water-soluble). This means that the high expense of effective supplements like methoxy isoflavone (and its deviants) to be reduced due to lower dosage requirements.
*Since this drug clears the body quickly, it was a favorite for tested competitors.
Masteron is a synthetic derivative of dihydrotestosterone, displaying a potent androgenic effect that is responsible for increases in muscle density and hardness and a moderate anabolic effect that creates a positive nitrogen balance in humans and promotes protein synthesis. Since it is a derivative of dihydrotestosterone, dromastolone does not aromatize in any dosage and thus it cannot be converted into estrogen. Therefore, estrogen-related water retention is eliminated. Mastaplex combines the fast-acting propionate form with the longer-acting enanthate form.
